The market growth can be attributed to several factors such as increasing prevalence of neuroblastoma in children, improvements in the healthcare infrastructure, and rising R&D activities are anticipated to further contribute to this substantial market growth between 2019 and 2030. However, high cost of this therapy is likely to restrain the growth of market to a certain extent. Market Industry Reports (MIR) has published a new report titled "Pediatric Neuroblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the Global Pediatric Neuroblastoma Treatment Market is estimated to account for over US$ 676.0 million by 2019. The market is anticipated to grow at a CAGR of ~8.6% from 2019 to 2030.
To obtain better insights regarding the market scenario, prominent players are increasingly focusing on collaborative initiatives with several institutes, research centers, and companies. For instance, In January 2020, EUSA Pharma and BeiGene, Ltd. announced that they have entered into an exclusive development and commercialization agreement for the orphan biologic products SYLVANT® (siltuximab) and QARZIBA® (dinutuximab beta) in Greater China. According to the American Society of Clinical Oncology (ASCO), in U.S., neuroblastoma is the 3rd most common cancer found in children, accounting for more than 6% of childhood cancer and nearly 800 new cases of neuroblastoma are reported in the U.S. each year. Therefore, the rising incidences of pediatric neuroblastoma can be a major factor contributing to the growth of market.
Major Key Players of the Pediatric Neuroblastoma Treatment Market are:
United Therapeutics Corporation, APEIRON Biologics AG., EUSA Pharma, CELLECTAR BIOSCIENCES, INC., Y-mAbs Therapeutics, Pfizer Inc., MacroGenics, Inc., Baxter, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Ltd. among others.
Read More @ http://www.sbwire.com/press-releases/pediatric-neuroblastoma-treatment-market-strategic-plan-for-positive-growth-2030-united-therapeutics-apeiron-biologics-1281474.htm
Rising R&D activities and rise in their private & public funding is expected to positively impact the global market. Prominent players are trying to encourage technological advancements to develop the next generation of cancer-targeting treatments through research & development collaborations. This has resulted in the identification of new tumor targets and innovative approaches for the treatment.
However, high cost related to therapy is one of the major factors hampering market growth. Increase in R&D activities and technological advancements related to the treatments have increased the survival rate, but unfortunately these advances come at a very high price. Patients with neuroblastoma undergo many rounds of complex and intensive treatment comprising of several cycles of chemotherapy, which may increase the duration of treatment. Longer the duration of treatment, the greater is the cost. This factor is expected to hamper the growth of market.
Major Types of Pediatric Neuroblastoma Treatment Market covered are:
Immunotherapy
Chemotherapy, and Radiation Therapy
Major Applications of Pediatric Neuroblastoma Treatment Market covered are:
Hospitals
Cancer Specialty Centers
Read More @ http://www.sbwire.com/press-releases/pediatric-neuroblastoma-treatment-market-strategic-plan-for-positive-growth-2030-united-therapeutics-apeiron-biologics-1281474.htm
To obtain better insights regarding the market scenario, prominent players are increasingly focusing on collaborative initiatives with several institutes, research centers, and companies. For instance, In January 2020, EUSA Pharma and BeiGene, Ltd. announced that they have entered into an exclusive development and commercialization agreement for the orphan biologic products SYLVANT® (siltuximab) and QARZIBA® (dinutuximab beta) in Greater China. According to the American Society of Clinical Oncology (ASCO), in U.S., neuroblastoma is the 3rd most common cancer found in children, accounting for more than 6% of childhood cancer and nearly 800 new cases of neuroblastoma are reported in the U.S. each year. Therefore, the rising incidences of pediatric neuroblastoma can be a major factor contributing to the growth of market.
Major Key Players of the Pediatric Neuroblastoma Treatment Market are:
United Therapeutics Corporation, APEIRON Biologics AG., EUSA Pharma, CELLECTAR BIOSCIENCES, INC., Y-mAbs Therapeutics, Pfizer Inc., MacroGenics, Inc., Baxter, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Ltd. among others.
Read More @ http://www.sbwire.com/press-releases/pediatric-neuroblastoma-treatment-market-strategic-plan-for-positive-growth-2030-united-therapeutics-apeiron-biologics-1281474.htm
Rising R&D activities and rise in their private & public funding is expected to positively impact the global market. Prominent players are trying to encourage technological advancements to develop the next generation of cancer-targeting treatments through research & development collaborations. This has resulted in the identification of new tumor targets and innovative approaches for the treatment.
However, high cost related to therapy is one of the major factors hampering market growth. Increase in R&D activities and technological advancements related to the treatments have increased the survival rate, but unfortunately these advances come at a very high price. Patients with neuroblastoma undergo many rounds of complex and intensive treatment comprising of several cycles of chemotherapy, which may increase the duration of treatment. Longer the duration of treatment, the greater is the cost. This factor is expected to hamper the growth of market.
Major Types of Pediatric Neuroblastoma Treatment Market covered are:
Immunotherapy
Chemotherapy, and Radiation Therapy
Major Applications of Pediatric Neuroblastoma Treatment Market covered are:
Hospitals
Cancer Specialty Centers
Read More @ http://www.sbwire.com/press-releases/pediatric-neuroblastoma-treatment-market-strategic-plan-for-positive-growth-2030-united-therapeutics-apeiron-biologics-1281474.htm
No comments:
Post a Comment